This study investigates advanced pancreatic neuroendocrine tumors. It explores how treatments guided by organoid drug sensitivity tests might affect these tumors.
The focus is on evaluating the effectiveness of chemotherapy and targeted therapy. It also looks at how well the organoid models match the patients' actual responses to the treatment.
- Who can participate: Adults aged 18 to 75 with advanced pancreatic neuroendocrine tumors may join. Participants must provide tumor tissue and have a performance status score of 0-2.
- Study details: Participants will provide tumor samples for organoid culture. The study will compare organoid responses to actual patient outcomes.